Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Hespecta vaccine study in HPV16-positive oropharyngeal squamous cell cancer after curative treatment
NL-OMON41192Phase 1Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2016
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of synthetic human papillomavirus 16 E6 peptide in oropharyngeal squamous cell carcinoma (OPSCC) and head and neck cancer (HNC) (4 arms), sponsored by Leiden University Medical Center. Primary endpoint: Biological activity: induction of HPV16 E6-specific T-cell immunity. Started Jan 2016; status: recruiting.
02
Drugs
synthetic human papillomavirus 16 E6 peptide
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON41192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41192.